Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktails show promise in slowing advanced kidney cancer

NCT ID NCT02811861

Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could delay cancer growth better than sunitinib alone. About 1,069 adults with advanced clear-cell kidney cancer took part, and the results help doctors choose the best first treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,069 people

The number who actually took part.

Started

Oct 2016

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histological or cytological confirmation of RCC with a clear-cell component (original tissue diagnosis of RCC is acceptable). 2. Documented evidence of advanced RCC. 3. At least 1 measurable target lesion according to RECIST 1.1 meeting the following criteria: * Lymph node (LN) lesion that measures at least 1 dimension as greater than or equal to (\>=) 1.5 cm in the short axis * Lymph node (LN) lesion that measures at least 1 dimension as greater than or equal to (\>=) 1.5 centimeter (cm) in the short axis * Non-nodal lesion that measures greater than or equal to (\>=) 1.0 cm in the longest diameter * The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST 1.1 to be deemed a target lesion. 3.Karnofsky Performance Status (KPS) of \>=70 4.Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal (\<=) 150/90 millimeter of mercury (mmHg) at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1 (C1/D1) 5.Adequate renal function defined as creatinine \<=1.5\*upper limit of normal (ULN); or for participants with creatinine greater than (\>) 1.5\*ULN, the calculated creatinine clearance \>=30 milliliters per minute (mL/min) (per the Cockcroft-Gault formula) is acceptable. 6.Adequate bone marrow function defined by: * Absolute neutrophil count (ANC) \>=1500/cubic millimeter (mm\^3) * Platelets \>=100,000/mm\^3 * Hemoglobin \>=9 grams per deciliter (g/dL) NOTE: Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the previous 2 weeks. 7.Adequate blood coagulation function defined by International Normalized ratio (INR) \<=1.5 unless participant is receiving anticoagulant therapy, as long as INR is within therapeutic range of intended use of anticoagulants. 8.Adequate liver function defined by: * Total bilirubin \<=1.5\*ULN except for unconjugated hyperbilirubinemia of Gilbert's syndrome. * Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \<=3\*ULN (in the case of liver metastases \<=5\*ULN), unless there are bone metastases. Participants with ALP values \>3\*ULN and known to have bone metastases can be included. 9.Provide written informed consent. 10.Willing and able to comply with all aspects of the protocol. Exclusion Criteria: 1. Participants who have received any systemic anticancer therapy for RCC, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agent. Prior adjuvant treatment with an investigational anticancer agent is not allowed unless the investigator can provide evidence of participant's randomization to placebo arm. 2. Participants with central nervous system (CNS) metastases are not eligible, unless they have completed local therapy (example, whole brain radiation therapy (WBRT), surgery or radiosurgery) and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of CNS metastases must be stable for at least 4 weeks before starting study treatment 3. Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months. Participants with history of localized \& low risk prostate cancer are allowed in the study if they were treated with curative intent and there is no prostate specific antigen (PSA) recurrence within the past 5 years 4. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start 5. Participants who are using other investigational agents or who had received investigational drugs \<=4 weeks prior to study treatment start. 6. Received a live vaccine within 30 days of planned start of study treatment (Cycle 1/Day 1). Examples of live vaccines include, but are not limited to, measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (example, FluMist®) are live attenuated vaccines and are not allowed. 7. Participants with proteinuria \>1+ on urine dipstick testing will undergo 24-h urine collection for quantitative assessment of proteinuria. Participants with urine protein \>=1 g/24 h will be ineligible 8. Fasting total cholesterol \>300 milligram per deciliter (mg/dL) (or ˃7.75 millimole per liter (mmol/L)) and/or fasting triglycerides level ˃2.5 x upper limit of normal (ULN). Note: these participants can be included after initiation or adjustment of lipid-lowering medication 9. Uncontrolled diabetes as defined by fasting glucose \>1.5 times the ULN. Note: these participants can be included after initiation or adjustment of glucose-lowering medication 10. Prolongation of corrected QT (QTc) interval to \>480 milliseconds (ms) 11. Participants who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy. 12. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib, everolimus, and/or sunitinib. 13. Bleeding or thrombotic disorders or participants at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy 14. Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug 15. Significant cardiovascular impairment within 12 months of the first dose of study drug: history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident, or cardiac arrhythmia associated with hemodynamic instability. The following is also excluded: left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multiple-gated acquisition MUGA scan or echocardiogram 16. Active infection (any infection requiring systemic treatment) 17. Participants known to be positive for Human Immunodeficiency Virus (HIV). 18. Known active Hepatitis B (example, Hepatitis B surface antigen (HBsAg) reactive) or Hepatitis C (example, hepatitis C virus ribonucleic acid (HCV RNA) \[qualitative\] is detected) 19. Known history of, or any evidence of, interstitial lung disease 20. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis 21. Participants with a diagnosis of immunodeficiency or who are receiving chronic systemic steroid therapy (doses exceeding 10 mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Physiologic doses of corticosteroids (up to 10 mg/day of prednisone or equivalent) may be used during the study 22. Active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (that is, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. 23. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] (or human chorionic gonadotropin \[hCG\]) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG \[or hCG\]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. 24. Females of childbearing potential who: * Do not agree to use a highly effective method of contraception for the entire study period and for 120 days after study discontinuation, that is: * total abstinence (if it is their preferred and usual lifestyle) * an intrauterine device (IUD) or hormone-releasing system (IUS) * a contraceptive implant * an oral contraceptive (with additional barrier method) OR * Do not have a vasectomized partner with confirmed azoospermia. For sites outside of the EU, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide. 25. Males who have not had a successful vasectomy (confirmed azoospermia) and do not agree to use condom + spermicide OR have a female partner who does not meet the criteria above (that is, is of childbearing potential and not practicing highly effective contraception throughout the study period), starting with the first dose of study therapy through 120 days after the last dose of study therapy, unless sexually abstinent. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant. 26. Known intolerance to any of the study drugs (or any of the excipients) 27. Participant has had an allogenic tissue/solid organ transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell carcinoma

Contacts and locations

Locations

  • A.O.U. Policlinico di Modena

    Modena, 41124, Italy

  • AKH - Medizinische Universität Wien

    Vienna, 1090, Austria

  • Adelaide and Meath Hospital Incorp The National Children's Hospital

    Dublin, Ireland

  • Antoni van Leeuwenhoek

    Amsterdam, 1066 CX, Netherlands

  • Asan Medical Center: Medical Oncology Department

    Seoul, South Korea

  • Asan Medical Center: Urology Department

    Seoul, South Korea

  • Assaf Harofeh Medical Center

    Be’er Ya‘aqov, Israel

  • Associates in Oncology & Hematology, PC

    Bethesda, Maryland, 20817, United States

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Azienda Ospedaliera San Camillo Forlanini

    Roma, Italy

  • Azienda Ospedaliera Santa Maria Degli Angeli

    Pordenone, 33170, Italy

  • Azienda Ospedaliera Universitaria Policlinico SantOrsola Malpighi

    Bologna, Italy

  • Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli

    Naples, 80131, Italy

  • Azienda Unità Sanitaria Locale- Ravenna

    Faenza, Ravenna, 48018, Italy

  • BC Cancer Agency Vancouver Centre

    Vancouver, British Columbia, V5Z 1H7, Canada

  • BHI of Omsk region "Clinical Oncology Dispensary"

    Omsk, 644013, Russia

  • Beatson West Of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Beaumont Hospital

    Dublin, Ireland

  • Boca Raton Community Hospital

    Boca Raton, Florida, 33486, United States

  • Boulevard du Professeur Jacques Monod

    Saint-Herblain, 4805, France

  • Box Hill Hospital

    Box Hill, Victoria, 3128, Australia

  • Broome Oncology

    Johnson City, New York, 13790, United States

  • CHU Strasbourg - Nouvel Hopital Civil

    Strasbourg, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes

    Lyon, France

  • Centre de santé et de services sociaux Champlain-Charles-Le Moyne

    Greenfield Park, Quebec, J4V 2H1, Canada

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Christie Hospital NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • Clinique Victor Hugo - Centre Jean Bernard

    Le Mans, France

  • Cork University Hospital,Wilton

    Cork, Ireland

  • Cotton-Oneil Clinical Research Center

    Topeka, Kansas, 66604, United States

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Department of Internal Medicine Division of Hematology/Oncology Cancer center 11F

    Seoul, South Korea

  • Domaine Universitaire

    Liège, 4000, Belgium

  • EISAI Trial site 1

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • EISAI Trial site 13

    Münster, North Rhine-Westphalia, 48149, Germany

  • EISAI Trial site 14

    Greifswald, Mecklenburg-Vorpommern, Germany

  • EISAI Trial site 2

    Homburg/Saar, Saarland, 66421, Germany

  • EISAI Trial site 4

    Stuttgart, Baden-Wurttemberg, 70174, Germany

  • EISAI Trial site 5

    Berlin, 12200, Germany

  • EISAI Trial site 6

    Frankfurt am Main, Hesse, 60590, Germany

  • EISAI Trial site 7

    München, Bavaria, 81377, Germany

  • EISAI Trial site 8

    Hanover, Lower Saxony, 30625, Germany

  • FBHI Privolzhskiy District Medical Centre FMBA of Russia

    Nizhny Novgorod, Russia

  • FSBI "Moscow scientific research oncology institute n.a. P.A. Gertsen" of MoH of RF

    Moscow, 125284, Russia

  • FSBI "National Medical Research Radiological Center" of the MoH of the RF

    Obninsk, 249036, Russia

  • FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Oncology

    Moscow, 115478, Russia

  • FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin - Department of Urology

    Moscow, Russia

  • Facility #1

    Aichi, Japan

  • Facility #1

    Akita, Japan

  • Facility #1

    Aomori, Japan

  • Facility #1

    Fukuoka, Japan

  • Facility #1

    Hiroshima, Japan

  • Facility #1

    Hokkaido, Japan

  • Facility #1

    Hyōgo, Japan

  • Facility #1

    Kagawa, Japan

  • Facility #1

    Nagasaki, Japan

  • Facility #1

    Nara, Japan

  • Facility #1

    Niigata, Japan

  • Facility #1

    Okayama, Japan

  • Facility #1

    Osaka, Japan

  • Facility #1

    Saitama, Japan

  • Facility #1

    Tokushima, Japan

  • Facility #1

    Tokyo, Japan

  • Facility #2

    Chiba, Japan

  • Facility #2

    Hokkaido, Japan

  • Facility #2

    Kanagawa, Japan

  • Facility #2

    Osaka, Japan

  • Facility #2

    Tokyo, Japan

  • Facility #3

    Kanagawa, Japan

  • Facility #3

    Tokyo, Japan

  • Facility #4

    Tokyo, Japan

  • Facility #5

    Tokyo, Japan

  • Facility #6

    Tokyo, Japan

  • Fakultni nemocnice Olomouc, Neurologicka klinika

    Olomouc, Czechia

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Florida Cancer Specialists

    Fort Myers, Florida, 33901, United States

  • Florida Cancer Specialists

    West Palm Beach, Florida, 33401, United States

  • Florida Cancer Specialists ( North Region)

    St. Petersburg, Florida, 33705, United States

  • Florida Hospital Cancer Institute

    Orlando, Florida, 32804, United States

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • GU Research Network

    Omaha, Nebraska, 68130, United States

  • GZA Ziekenhuizen - Campus Sint-Augustinus

    Wilrijk, 2610, Belgium

  • General Hospital Papageorgiou

    Thessaloniki, 56429, Greece

  • General Hospital of Athens "Alexandra"

    Athens, 11528, Greece

  • Guy's Hospital

    London, United Kingdom

  • Hackensack Medical Center

    Hackensack, New Jersey, 07601, United States

  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC

    Overland Park, Kansas, 66209, United States

  • Healthcare Research Network III, LLC

    Tinley Park, Illinois, 60487, United States

  • Hopital Europeen Georges Pompidou

    Paris, France

  • Hopital la Petie Salpetriere

    Paris, cedex 13 75651, France

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, 10003, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, 33011, Spain

  • Hospital Universitario Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario HM Madrid Sanchinarro

    Madrid, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • I.R.C.S.S Fondazione Maugeri

    Pavia, Italy

  • ICO - Site Paul Papin

    Angers, Maine Et Loire, 49055, France

  • ICO l'Hospitalet - Hospital Duran I Reynals

    Barcelona, 08908, Spain

  • ICON Cancer Foundation

    South Brisbane, Australia

  • Imeldaziekenhuis

    Bonheiden, Belgium

  • Inselspital - Universitaetsspital Bern

    Bern, Switzerland

  • Institut Jules Bordet

    Brussels, 1000, Belgium

  • Institut Regional du Cancer de Montpellier

    Montpellier, France

  • Interbalkan Hospital of Thessaloniki

    Thessaloniki, 57001, Greece

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Italy

  • Istituto Nazionale per la Ricerca sul Cancro di Genova

    Genova, 16132, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST

    Meldola, Italy

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, 3500, Belgium

  • Joliet Oncology - Hematology Associates

    Joliet, Illinois, 60435, United States

  • Karmanos Cancer Center

    Detroit, Michigan, 48201, United States

  • Krankenhaus der barmherzigen Schwestern Linz

    Linz, Austria

  • Kyungpook National University Chilgok Hospital

    Daegu, 41404, South Korea

  • London Institute of Health Sciences

    London, Ontario, N6A4L6, Canada

  • MD Anderson Cancer Centre

    Madrid, Spain

  • Macquarie University Hospital

    Macquarie Park, Australia

  • Masarykuv onkologicky ustav

    Brno, Czechia

  • Massachusetts General Hospital- MGH

    Boston, Massachusetts, 02214, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29412, United States

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Mission Hospital_ Cancer Care of Western North Carolina

    Asheville, North Carolina, 28801, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • Mount Sinai Medical Center

    Miami Beach, Florida, 33136, United States

  • National Cancer Center

    Goyang-si, South Korea

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68130, United States

  • Nemocnice Na Bulovce

    Prague, Czechia

  • O.L.V Ziekenhuis

    Aalst, Belgium

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Oncologia

    Valencia, 46009, Spain

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242, United States

  • Ospedale San Donato

    Arezzo, Italy

  • Ottawa Hospital Cancer Centre

    Ottawa, Ontario, K1H 8, Canada

  • Presidio Ospedaliero Vito Fazzi

    Lecce, 73100, Italy

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, 49100, Israel

  • Rambam MC

    Haifa, Israel

  • Rosewell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Royal Bournemouth General Hospital

    Bournemouth, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • Royal Hobart Hospital

    Hobart, Australia

  • SBHI of Novosibirsk region "Novosibirsk Regional Oncological Dispensary"

    Novosibirsk, 630108, Russia

  • SCRI - Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • SPWSZ w Szczecinie im. Marii Sklodowskiej-Curie

    Szczecin, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

    Lublin, Poland

  • Samsung Medical Center

    Seoul, South Korea

  • Sapir Medical Center, Meir Hospital

    Kfar Saba, Israel

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • St. James's University Hospital

    Leeds, LS9 7TF, United Kingdom

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 4A6, Canada

  • Stanford School of Medicine

    Stanford, California, 94305-5826, United States

  • Sunnybrook Research Institute - University of Toronto

    Toronto, Ontario, M4N 3M5, Canada

  • Sunshine Hospital

    St Albans, Australia

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Texas Oncology PA

    Fort Worth, Texas, 76104, United States

  • Texas Oncology PA - McAllen

    McAllen, Texas, 78503, United States

  • Texas Oncology PA - Paris

    Paris, Texas, 75460, United States

  • Texas Oncology PA - Tyler

    Tyler, Texas, 75702, United States

  • Texas Oncology, P.A.

    Dallas, Texas, 75231, United States

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • Thomayerova nemocnice

    Prague, Czechia

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • USOR Texas Oncology

    The Woodlands, Texas, 77380, United States

  • Universita Campus Bio-Medico di Roma

    Rome, Italy

  • University Hospital Galway

    Galway, Ireland

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Patras Medical School

    Pátrai, 26504, Greece

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • VU Medisch Centrum

    Amsterdam, 1081 HV, Netherlands

  • Velindre Cancer Centre

    Cardiff, United Kingdom

  • Weill Cornell Medical College New York Presbyterian Hospital

    New York, New York, 10021, United States

  • Western General Hospital

    Edinburgh, United Kingdom

  • ZNA Middelheim

    Antwerp, 2260, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.